$HOSEA\ Aim\ I-Report$

Simon Fontaine

September 19, 2022


Contents

1 Overall performance		
2	Comparison to HUNT, Kunzmann and Guidelines 2.1 Full test data 2.2 Complete test patients 2.3 Representative sample	8
3	Calibration	14
4 Thresholds		
5	Stratification by identity groups 5.1 Age 5.2 Sex 5.3 Race	24
6	Cancer stage	30
7	Variable importance 7.1 Gain VI	
8	Years prior	34

1 Overall performance


Cancer type: ANY Dataset: test, all

Cases: 2848/2567069 AUC: 0.800 [0.793,0.807]




Cancer type: EAC Dataset: test, all

Cases: 2076/2567069 AUC: 0.802 [0.794,0.811]




Cancer type: EGJAC Dataset: test, all


Cases: 772/2567069 AUC: 0.769 [0.755,0.783]




2 Comparison to HUNT, Kunzmann and Guidelines

2.1 Full test data










2.2 Complete test patients

w.r.t. HUNT, Kunzmann, & Guidelines (i.e., requires age, sex, GERD, bmi, smoking, etc.)










2.3 Representative sample

w.r.t. sex and prevalance ratio by sex









Calibration 3

Cancer type: ANY Dataset: test, all Cases: 2848/2567069

HL: H=53.04, df=50, p=0.358




Cancer type: EAC Dataset: test, all Cases: 2076/2567069 HL: H=44.41, df=50, p=0.696



Cancer type: EGJAC Dataset: test, all Cases: 772/2567069

HL: H=64.74, df=50, p=0.079



4 Thresholds


ANY Threshold	TPR	PPV	DetPrevalence
0	100.00	0.11	100.00
5	99.54	0.13	82.38
10	99.40	0.14	78.88
15	99.09	0.15	75.76
20	98.60	0.15	72.73
25	97.68	0.16	69.71
30	97.16	0.16	66.67
35	96.10 95.19	$0.17 \\ 0.17$	63.70 60.83
40 45	93.19 94.24	0.17	58.08
50	93.22	0.19	55.47
55	92.17	0.19	52.98
60	91.12	0.20	50.60
65	89.68	0.21	48.36
70	88.24	0.21	46.22
75	86.73	0.22	44.21
80	85.32	0.22	42.32
85	84.23	0.23	40.53
90	82.94	0.24	38.87
95	81.64	0.24	37.30
100	80.65	0.25	35.81
105	79.39	0.26	34.39
110	$77.98 \\ 76.65$	0.26	33.06
115 120	75.42	$0.27 \\ 0.27$	$31.78 \\ 30.57$
125	73.98	0.28	29.41
130	72.75	0.29	28.30
135	71.52	0.29	27.24
140	70.19	0.30	26.23
145	68.71	0.30	25.24
150	67.10	0.31	24.30
155	65.77	0.31	23.39
160	64.64	0.32	22.51
165 170	$63.38 \\ 62.08$	$0.32 \\ 0.33$	$21.66 \\ 20.85$
175 180	$61.17 \\ 59.59$	$0.34 \\ 0.34$	20.07 19.33
185	58.39	0.35	18.61
190	57.09	0.35	17.93
195	56.04	0.36	17.27
200	54.95	0.37	16.64
220	50.49	0.39	14.38
240	46.52	0.41	12.50
260 280	$42.84 \\ 39.54$	$0.44 \\ 0.46$	$10.92 \\ 9.56$
300 320	$37.18 \\ 34.02$	$0.49 \\ 0.51$	$8.40 \\ 7.41$
340	31.07	0.53	6.56
360	29.14	0.56	5.81
380	26.83	0.58	5.16
400	24.72	0.60	4.59
420	23.24	0.63	4.09
440	21.38	0.65	3.65
460	19.73	0.67	3.26
480	18.64	0.71	2.92
500	17.38	0.74	2.62
550	14.54	0.81	2.00
600	12.46	0.90	1.53
650 700	$10.29 \\ 8.25$	$0.96 \\ 0.98$	$\frac{1.19}{0.93}$
750			0.73
750 800	$7.16 \\ 5.76$	$\frac{1.08}{1.09}$	$0.73 \\ 0.58$
850	4.88	1.16	0.47
900	4.39	1.30	0.37
950	3.79	1.38	0.31


EAC Threshold	TPR	PPV	DetPrevalence
0	100.00	0.08	100.00
5	99.71	0.10	79.96
10 15	99.18 98.55	$0.11 \\ 0.11$	$75.25 \\ 71.17$
20	97.59	0.12	67.18
25	96.15	0.12	63.30
30	94.75	0.13	59.59
35	93.55	0.13	56.09
40 45	$92.05 \\ 90.37$	$0.14 \\ 0.15$	$52.76 \\ 49.65$
50	88.87		
55	86.95	$0.15 \\ 0.16$	$46.76 \\ 44.05$
60	84.97	0.17	41.56
65	83.33	0.17	39.26
70	81.79	0.18	37.16
75	80.39	0.18	$35.24 \\ 33.45$
80 85	$78.85 \\ 77.31$	$0.19 \\ 0.20$	35.45 31.80
90	75.53	0.20	30.23
95	73.70	0.21	28.77
100	72.11	0.21	27.39
105	70.42	0.22	26.08
110 115	$68.64 \\ 67.29$	$0.22 \\ 0.23$	$24.82 \\ 23.63$
120	65.70	0.24	22.50
125	64.07	0.24	21.43
130	62.19	0.25	20.41
135 140	$60.16 \\ 58.67$	$0.25 \\ 0.26$	19.43 18.50
145	57.42	0.26	17.62
150	56.02	0.27	16.78
155	54.62	0.28	16.00
160	53.42	0.28	15.27
165 170	51.73 50.43	$0.29 \\ 0.29$	14.57 13.90
175	49.37	0.30	13.27
180	47.54	0.30	12.69
185	45.86	0.31	12.13
190 195	44.89 43.93	$0.31 \\ 0.32$	$11.61 \\ 11.10$
200	42.82	0.33	10.62
220	38.97	0.35	8.96
240	35.50	0.38	7.59
260 280	$32.23 \\ 28.37$	$0.40 \\ 0.42$	$6.47 \\ 5.52$
300	25.72	0.44	4.74
320	23.03	0.44	4.08
340	20.86	0.48	3.52
360 380	$19.08 \\ 17.15$	$0.51 \\ 0.53$	$\frac{3.04}{2.64}$
400 420	$15.90 \\ 14.60$	$0.56 \\ 0.59$	$\frac{2.29}{1.99}$
440	12.96	0.60	1.73
460	11.85	0.63	1.52
480	10.69	0.65	1.33
500 550	$9.78 \\ 7.66$	$0.68 \\ 0.73$	$\frac{1.16}{0.85}$
600	5.92	$0.73 \\ 0.77$	0.62
650	4.53	0.79	0.47
700	3.85	0.90	0.35
750 800	$\frac{3.32}{2.46}$	1.01	0.27
800 850	$\frac{2.46}{1.83}$	$0.98 \\ 0.95$	$0.20 \\ 0.16$
900	1.49	1.01	0.12
950	1.25	1.08	0.09
1000	1.16	1.27	0.07


EGJAC Threshold	TPR	PPV	DetPrevalence
0	100.00	0.03	100.00
5	98.58	0.04	76.82
10	96.11	0.04	65.06
15	89.25	0.05	53.93
20	83.68	0.06	44.85
25	77.72	0.06	37.42
30	70.85	0.07	31.35
35	64.64	0.07	26.37
40 45	58.55 53.89	$0.08 \\ 0.09$	$\frac{22.29}{18.91}$
50	48.32	0.09	16.12
55	43.26	0.09	13.78
60	38.99	0.10	11.84
65	34.97	0.10	10.23
70	30.83	0.10	8.87
75	27.85	0.11	7.71
80	25.26	0.11	6.73
85	22.54	0.11	5.90
90	19.56	0.11	5.19
95	18.01	0.12	4.58
100	$16.84 \\ 15.41$	$0.12 \\ 0.13$	$\frac{4.06}{3.60}$
105 110	$15.41 \\ 14.51$	$0.13 \\ 0.14$	$\frac{3.60}{3.20}$
115	14.51 12.82	$0.14 \\ 0.14$	$\frac{3.20}{2.86}$
120	11.40	0.14	2.55
125	10.23	0.13	2.28
130	8.94	0.13	2.05
135	8.16	0.13	1.84
140	7.38	0.13	1.66
145	6.87	0.14	1.50
150	6.35	0.14	1.36
155	5.96	0.15	1.23
160	5.83	0.16	1.12
165 170	$\frac{5.05}{4.79}$	$0.15 \\ 0.16$	$\begin{array}{c} 1.02 \\ 0.92 \end{array}$
175	4.27	0.15	0.84
180	4.27	0.17	0.77
185	4.15	0.18	0.70
190	4.02	0.19	0.64
195	3.63	0.19	0.59
200	3.37	0.19	0.54
220	2.46	0.19	0.39
240	2.07	0.22	0.28
$260 \\ 280$	$\frac{1.55}{1.17}$	$0.22 \\ 0.22$	$0.21 \\ 0.16$
300	0.78	0.20	0.12
320	0.78	0.26	0.09
340	0.39	0.17	0.07
360	0.39	0.21	0.05
380	0.39	0.27	0.04
400	0.39	0.34	0.03
420	0.13	0.14	0.03
440	0.13	0.18	0.02
460	0.13	0.22	0.02
480	0.13	0.28	0.01
500 550	$0.13 \\ 0.13$	$0.34 \\ 0.53$	$0.01 \\ 0.01$
600	$0.13 \\ 0.00$	0.53 0.00	$0.01 \\ 0.00$
650	0.00	0.00	0.00
700	0.00	0.00	0.00
750	0.00	0.00	0.00
800	0.00	0.00	0.00
850	0.00	0.00	0.00
900	0.00	0.00	0.00
950	0.00	0.00	0.00
1000	0.00	0.00	0.00

5 Stratification by identity groups


5.1 Age










5.2 Sex









5.3 Race







6 Cancer stage

 $NB:\ the\ discrepancy\ in\ number\ of\ cases\ between\ I+\ and\ Any\ comes\ from\ the\ fact\ that\ some\ were\ classified\ as\ unknown\ stage\ according\ to\ the\ provided\ staging.$


ANY Stage	Test. AUC	Nb. cases
Any	0.799 [0.792,0.807]	2818
I II III IV	0.831 [0.815,0.847] 0.813 [0.796,0.831] 0.803 [0.791,0.816] 0.793 [0.782,0.804]	495 435 878 1244
$\begin{array}{c} I+\\ II+\\ III+\\ IV+ \end{array}$	0.801 [0.793,0.808] 0.796 [0.788,0.804] 0.794 [0.785,0.803] 0.793 [0.782,0.804]	2448 2169 1950 1244

EAC Stage	Test. AUC	Nb. cases
Any	0.803 [0.794,0.811]	2054
I II III IV	0.838 [0.820,0.856] 0.816 [0.795,0.837] 0.804 [0.790,0.819] 0.797 [0.785,0.810]	350 302 650 913
$\begin{array}{c} I+\\ II+\\ III+\\ IV+ \end{array}$	0.803 [0.794,0.811] 0.797 [0.788,0.807] 0.796 [0.786,0.806] 0.797 [0.785,0.810]	1813 1608 1451 913


EGJA Stage	.C Test. AUC	Nb. cases
Any	0.768 [0.754,0.782]	764
I	0.789 [0.756,0.821]	145
II	0.788 [0.752,0.824]	133
III	0.770 [0.744,0.796]	228
IV	0.762 [0.740,0.785]	331
I+	0.770 [0.754,0.786]	635
II+	0.767 [0.750,0.784]	561
III+	0.763 [0.745,0.781]	499
IV+	0.762 [0.740,0.785]	331

7 Variable importance

7.1 Gain VI



7.2 SHAP VI



8 Years prior

